Teladoc (TDOC) closed at $153.32 in the latest trading session, marking a -0.98% move from the prior day. This change lagged the S&P 500's 0.82% gain on the day.Prior to today's trading, shares of the telehealth services provider had lost 1.78% over the past month. This has was narrower than the Medical sector's loss of 2.96% and lagged the S&P 500's gain of 3.89% in that time.Wall Street will be looking for positivity from TDOC as it approaches its next earnings report date. This is expected to be July 27, 2021. On that day, TDOC is projected to report earnings of -$0.59 per share, which would represent a year-over-year decline of 73.53%. Meanwhile, our latest consensus estimate is calling for revenue of $500.97 million, up 107.85% from the prior-year quarter.TDOC's full-year Zacks Consensus Estimates are calling for earnings of -$3.03 per share and revenue of $2.01 billion. These results would represent year-over-year changes of -168.14% and +83.76%, respectively.Any recent changes to analyst estimates for TDOC should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.39% lower. TDOC is currently sporting a Zacks Rank of #4 (Sell).The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 94, putting it in the top 38% of all 250+ industries.The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teladoc Health, Inc. (TDOC): Free Stock Analysis Report To read this article on Zacks.com click here.